GRC and Total Data Centre Solutions Partner to Expand Data Centre Liquid Immersion Cooling in Europe
20.10.2020 09:00:00 EEST | Business Wire | Press release
GRC (Green Revolution Cooling), the single-phase immersion-cooling authority® for data centres, today announces a new partnership contract with Total Data Centre Solutions (TDCS), a leading provider of mission critical and innovative infrastructure solutions for Data Centres throughout Europe and the Nordic region focused on carbon reduction and energy efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005928/en/
GRC ICEraQ immersion-cooling system with rack-mounted service rails for easy maintenance and hot swaps. (Photo: Business Wire)
Through the partnership, TDCS will act as the agent for GRC in Europe, selling GRC’s ICEraQ® Micro-Modular, Rack-Based Immersion-Cooling Systems and ICEtank® Modular, Containerised data centres to clients primarily in the UK, the Nordic region, Germany and Luxembourg. Additionally, this new partnership now enables GRC to engage and support European data centre customers with a local European presence.
“GRC is delighted to partner with TDCS,” said Jim Weynand, Chief Revenue Officer, GRC. “The proliferation of AI, 5G, Edge computing, reduced carbon emissions, and more throughout Europe present new challenges for both legacy and new data centre builds. Our partnership with TDCS will ensure clients throughout Europe can seamlessly integrate immersion cooling into their existing infrastructures.”
After thoroughly assessing various immersion cooling solutions on the market, TDCS recognized that GRC’s immersion-cooling technology is a differentiator that brings value to their existing and potential clients. European clients can now acquire GRC’s immersion-cooling systems through TDCS in order to reduce energy use or power consumption, solve power and space density challenges, cut energy cooling costs significantly and place HPC compute close to where it’s needed and secure other benefits of GRC’s game-changing immersion-cooling solutions. Being the longest established immersion cooling company, with 11+ years’ experience and many blue-chip clients including The US Government, the US Air Force, and approved by most global server manufacturers – take out the fan and reap all the awards.
“It’s exciting to build this new partnership with GRC,” said Jonathan Evans, Founder of TDCS. “Joining GRC as an agent partner is an opportunity for us to offer clients best-of-breed single-phase liquid immersion cooling technology. We are passionate about reducing the carbon footprint and the OpEx of each, of our clients. The partnership of GRC and TDCS helps solve carbon and cost issues facing all data center owners and operators, which perfectly complements our sustainability portfolio of offerings from technologies to data centres."
About GRC
GRC is the immersion cooling authority®. The company's patented immersion-cooling technology radically simplifies deployment of data centre cooling infrastructure. By eliminating the need for chillers, CRACs, air handlers, humidity controls and other conventional cooling components, enterprises reduce their data centre design, build, energy, and maintenance costs. GRC’s solutions are deployed in seventeen countries and are ideal for next-gen applications platforms, including artificial intelligence, blockchain, HPC, 5G, and other Edge Computing and core applications. Their systems are environmentally resilient, sustainable, and space saving, making it possible to deploy the solution in virtually any location with minimal lead time. Visit http://grcooling.com for more information.
About Total Datacentre Solutions
TDCS is an End to End Data Centre Consultancy, founded in 2002. Specialising in reducing a client’s IT carbon footprint and CapEx/OpEx with new technologies. TDCS comprises a team of data centre business professionals, many with 30+ years of industry experience. Our aim is to provide clients with innovative technologies to help reduce their carbon footprints and optimize their CapEx/OpEx. Visit https://www.totaldatacentresolutions.co.uk for more information
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005928/en/
Contact information
Milldam Public Relations
Adam Waitkunas
978-828-8304 (mobile)
adam.waitkunas@milldampr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom